PARACEST Agents: Optimization for Human MR Imaging
PARACEST Agents: Optimization for Human MR Imaging
批准号:
8651911
负责人:
ROBERT E LENKINSKI
金额:
$84.55万
依托单位国家:
美国
项目类别:
财政年份:
2006
资助国家:
美国
项目状态:
已结题
起止时间:
2006-09-01 至 2016-03-31
关键词:
AccelerationAddressAlbuminsAnimalsAreaBindingBlood VesselsBuffersCase StudyChemicalsChemistryClinicalContrast MediaDetectionDevelopmentDrug KineticsEnvironmentEuropeEvaluationFamily suidaeFrequenciesFundingGadoliniumGoalsGrantGuidelinesHeadHumanHypoxiaImageIn VitroInstitutionInternationalIsraelKidneyKineticsKneeKnowledgeLabelLanthanoid Series ElementsLeadLigandsLiverMagnetic Resonance ImagingMalignant NeoplasmsMeasuresMedical centerMethodologyMethodsModelingMolecular WeightOxidation-ReductionPaperPerfusionPhysiologic pulsePlayPolymersProcessProgress ReportsPropertyProteinsPublishingRadioRattusResearchResearch PersonnelRoleSideSignal TransductionSpin LabelsSystemTestingTheoretical modelTimeTissue ModelTissuesToxic effectValidationVirionWaterabsorptionbasedesignextracellulargadolinium 1,4,7,10-tetraazacyclododecane-N,N&apos,N&apos&apos,N&apos&apos&apos-tetraacetategadolinium oxideimaging modalityin vivoin vivo imagingirradiationmeetingsmethod developmentmolecular imagingnovel strategiespublic health relevanceresearch studysensorsimulationtheoriestumor
中文摘要
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): Paramagnetic chemical exchange saturation transfer (PARACEST) agents offer a potential new paradigm in MR imaging. An advantage to this class of agents is the ability to switch each agent on or off through selective RF irradiation applied at the frequency of either its bound water resonance or an exchanging NH group. In their "off" state, i.e. when not specifically irradiated, PARACEST agents will not interfere with conventional MR imaging sequences, with or without gadolinium. In principle, PARACEST agents can be tailored to each application because their effects depend on their water exchange rates, and these rates can be modified using rational chemical principles. This feature also makes them an attractive platform for the development of responsive agents. The goal of this BRP is to realize the full potential of these compounds as contrast agents in vivo, by systematically addressing a number of basic, theoretical and practical questions. These include establishing the relationships among the magnitude of the effect measured in an imaging experiment and the water exchange lifetime, the magnitude of the chemical shift difference between the bound and bulk water, the strength of the saturating RF field, SAR, concentration, and local environment in vivo. This partnership is made up of two academic institutions and an industrial collaborator. The three main overlapping and interactive areas of focus are: lanthanide chemistry, which will be carried out at UT Dallas (UTD); Pulse sequence implementation, theory, simulations and in vitro validation which will be carried out primarily at the General Electric Global Research Center (GEGRC) and in vivo validation carried out primarily at the BIDMC. Dean Sherry (Project Leader, UTD) is an internationally recognized expert in the synthesis and characterization of lanthanide chelates and has expertise in basic NMR exchange theory. Thomas Dixon and Ileana Hancu (Project Leaders, GEGRC) are both experts in NMR and MR imaging. Robert Lenkinski (PI, BIDMC) is an NMR spectroscopist with expertise both in lanthanide agents and MR imaging. David Alsop (Lead Investigator, BIDMC) has a long track record in optimizing Arterial Spin Labeling perfusion studies, where the detection of small signal intensity changes in the presence of RF irradiation is necessary. Over the past several years, this team has been collaborating on the theoretical and practical aspects of the PARACEST effect. The successful completion of this project will result in three agents (intravascular, pH, and Redox responsive) and MR acquisition strategies for use in human studies.
PUBLIC HEALTH RELEVANCE: Paramagnetic chemical exchange saturation transfer (PARACEST) agents offer a potential new paradigm in MR imaging. The goal of this BRP is to realize the full potential of these compounds as contrast agents in vivo, by systematically addressing a number of basic, theoretical and practical questions. The successful completion of this project will result in three agents (intravascular, pH, and Redox responsive) and MR acquisition strategies for use in human studies.
期刊论文(8)
专著(0)
科研奖励(0)
会议论文
登录
查看更多内容
DOI:
10.1002/cmdc.201402034
发表时间:
2014-06
期刊:
CHEMMEDCHEM
影响因子:
3.4
作者:
[Do, Quyen N., Ratnakar, James S., Kovacs, Zoltan, Sherry, A. Dean]
通讯作者:
Sherry, A. Dean
DOI:
10.1002/mrm.22912
发表时间:
2011-11
期刊:
MAGNETIC RESONANCE IN MEDICINE
影响因子:
3.3
作者:
[Scheidegger, Rachel, Vinogradov, Elena, Alsop, David C.]
通讯作者:
Alsop, David C.
DOI:
10.1002/mrm.25780
发表时间:
2016-05
期刊:
Magnetic resonance in medicine
影响因子:
3.3
作者:
[Liu Z, Dimitrov IE, Lenkinski RE, Hajibeigi A, Vinogradov E]
通讯作者:
Vinogradov E
DOI:
10.1039/c3cc42452a
发表时间:
2013-07-21
期刊:
Chemical communications (Cambridge, England)
影响因子:
--
作者:
[Zhang S, Zhou K, Huang G, Takahashi M, Sherry AD, Gao J]
通讯作者:
Gao J
DOI:
10.1002/mrm.25091
发表时间:
2014-03
期刊:
MAGNETIC RESONANCE IN MEDICINE
影响因子:
3.3
作者:
[Soesbe, Todd C., Ratnakar, S. James, Milne, Mark, Zhang, Shanrong, Do, Quyen N., Kovacs, Zoltan, Sherry, A. Dean]
通讯作者:
Sherry, A. Dean
共 7 条
OPTIMIZING PARACEST AGENTS FOR HUMAN MR IMAGING
-
批准号:8363909
-
项目类别:
-
资助金额:$1.61万
-
财政年份:2011
-
负责人:ROBERT E LENKINSKI
-
依托单位:
EXTERNAL ADVISORY COMMITTEE
-
批准号:8363922
-
项目类别:
-
资助金额:$0.8万
-
财政年份:2011
-
负责人:ROBERT E LENKINSKI
-
依托单位:
OPTIMIZING PARACEST AGENTS FOR HUMAN MR IMAGING
-
批准号:8171660
-
项目类别:
-
资助金额:$1.05万
-
财政年份:2010
-
负责人:ROBERT E LENKINSKI
-
依托单位:
EXTERNAL ADVISORY COMMITTEE
-
批准号:8171673
-
项目类别:
-
资助金额:$0.52万
-
财政年份:2010
-
负责人:ROBERT E LENKINSKI
-
依托单位:
OPTIMIZING PARACEST AGENTS FOR HUMAN MR IMAGING
-
批准号:7956980
-
项目类别:
-
资助金额:$1.78万
-
财政年份:2009
-
负责人:ROBERT E LENKINSKI
-
依托单位:
EXTERNAL ADVISORY COMMITTEE
-
批准号:7956997
-
项目类别:
-
资助金额:$0.89万
-
财政年份:2009
-
负责人:ROBERT E LENKINSKI
-
依托单位:
PARACEST AGENTS: OPTIMIZATION FOR HUMAN MR IMAGING
-
批准号:7724130
-
项目类别:
-
资助金额:$1.05万
-
财政年份:2008
-
负责人:ROBERT E LENKINSKI
-
依托单位:
PARACEST AGENTS: OPTIMIZATION FOR HUMAN MR IMAGING
-
批准号:7600866
-
项目类别:
-
资助金额:$1.51万
-
财政年份:2007
-
负责人:ROBERT E LENKINSKI
-
依托单位:
PARACEST Agents: Optimization for Human MR Imaging
-
批准号:8431760
-
项目类别:
-
资助金额:$82.82万
-
财政年份:2006
-
负责人:ROBERT E LENKINSKI
-
依托单位:
PARACEST Agents: Optimization for Human MR Imaging
-
批准号:7804280
-
项目类别:
-
资助金额:$98.64万
-
财政年份:2006
-
负责人:ROBERT E LENKINSKI
-
依托单位:
PARACEST AGENTS: OPTIMIZATION FOR HUMAN MR IMAGING
-
批准号:7357909
-
项目类别:
-
资助金额:$1.17万
-
财政年份:2006
-
负责人:ROBERT E LENKINSKI
-
依托单位:
PARACEST Agents: Optimization for Human MR Imaging
-
批准号:7476265
-
项目类别:
-
资助金额:$100.52万
-
财政年份:2006
-
负责人:ROBERT E LENKINSKI
-
依托单位:
PARACEST Agents: Optimization for Human MR Imaging
-
批准号:7125381
-
项目类别:
-
资助金额:$102.8万
-
财政年份:2006
-
负责人:ROBERT E LENKINSKI
-
依托单位:
PARACEST Agents: Optimization for Human MR Imaging
-
批准号:8053757
-
项目类别:
-
资助金额:$89.62万
-
财政年份:2006
-
负责人:ROBERT E LENKINSKI
-
依托单位:
PARACEST Agents: Optimization for Human MR Imaging
-
批准号:7281683
-
项目类别:
-
资助金额:$98.67万
-
财政年份:2006
-
负责人:ROBERT E LENKINSKI
-
依托单位:
PARACEST Agents: Optimization for Human MR Imaging
-
批准号:8250400
-
项目类别:
-
资助金额:$88.01万
-
财政年份:2006
-
负责人:ROBERT E LENKINSKI
-
依托单位:
Multivoxel MRS of Human Breast Cancer at 3T.
-
批准号:6778668
-
项目类别:
-
资助金额:$34.85万
-
财政年份:2004
-
负责人:ROBERT E LENKINSKI
-
依托单位:
Multivoxel MRS of Human Breast Cancer at 3T.
-
批准号:6891291
-
项目类别:
-
资助金额:$34.85万
-
财政年份:2004
-
负责人:ROBERT E LENKINSKI
-
依托单位:
Multivoxel MRS of Human Breast Cancer at 3T.
-
批准号:7080471
-
项目类别:
-
资助金额:$34.03万
-
财政年份:2004
-
负责人:ROBERT E LENKINSKI
-
依托单位:
MR SPECTROSCOPY OF SUSPICIOUS BREAST MASSES
-
批准号:6315086
-
项目类别:
-
资助金额:$20.51万
-
财政年份:1997
-
负责人:ROBERT E LENKINSKI
-
依托单位:
海外基金